[go: up one dir, main page]

FI961976A7 - Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina - Google Patents

Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina Download PDF

Info

Publication number
FI961976A7
FI961976A7 FI961976A FI961976A FI961976A7 FI 961976 A7 FI961976 A7 FI 961976A7 FI 961976 A FI961976 A FI 961976A FI 961976 A FI961976 A FI 961976A FI 961976 A7 FI961976 A7 FI 961976A7
Authority
FI
Finland
Prior art keywords
metalloproteinases
inhibitors
therapeutic use
peptidyl compounds
peptidyl
Prior art date
Application number
FI961976A
Other languages
English (en)
Swedish (sv)
Other versions
FI961976A0 (fi
Inventor
John Montana
David Alan Owen
Jonathon Dickens
Andrew Douglas Baxter
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of FI961976A0 publication Critical patent/FI961976A0/fi
Publication of FI961976A7 publication Critical patent/FI961976A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI961976A 1993-11-10 1996-05-09 Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina FI961976A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323165A GB9323165D0 (en) 1993-11-10 1993-11-10 Compounds
PCT/GB1994/002471 WO1995013289A1 (en) 1993-11-10 1994-11-10 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases

Publications (2)

Publication Number Publication Date
FI961976A0 FI961976A0 (fi) 1996-05-09
FI961976A7 true FI961976A7 (fi) 1996-05-09

Family

ID=10744943

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961976A FI961976A7 (fi) 1993-11-10 1996-05-09 Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina

Country Status (21)

Country Link
US (1) US5853623A (fi)
EP (1) EP0728144B1 (fi)
JP (1) JPH09505041A (fi)
KR (1) KR960705843A (fi)
CN (1) CN1134705A (fi)
AT (1) ATE188969T1 (fi)
AU (1) AU679286B2 (fi)
BR (1) BR9408025A (fi)
CA (1) CA2173470A1 (fi)
CZ (1) CZ287780B6 (fi)
DE (1) DE69422726T2 (fi)
DK (1) DK0728144T3 (fi)
ES (1) ES2143611T3 (fi)
FI (1) FI961976A7 (fi)
GB (1) GB9323165D0 (fi)
GR (1) GR3033103T3 (fi)
HU (1) HU217344B1 (fi)
NO (1) NO961888L (fi)
PL (1) PL180403B1 (fi)
PT (1) PT728144E (fi)
WO (1) WO1995013289A1 (fi)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687436B2 (en) * 1993-08-23 1998-02-26 Immunex Corporation Inhibitors of TNF-alpha secretion
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
BR9509237A (pt) * 1994-10-05 1997-10-21 Chiroscience Ltd Compostos peptidila e seu uso terapêutico como inibidores de metaloproteases
CA2217850A1 (en) * 1995-05-10 1996-11-14 Chirotech Technology Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
JPH11504646A (ja) * 1995-05-10 1999-04-27 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
DE69627483T2 (de) * 1995-05-10 2004-04-01 Darwin Discovery Ltd., Slough Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
AU7139996A (en) * 1995-10-05 1997-04-28 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
IL123430A (en) * 1995-10-05 2001-04-30 Darwin Discovery Ltd Theo-converted peptides as inhibitors for metallic proteinases and TNF release
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
BR9611636A (pt) * 1995-11-22 1999-12-28 Darwin Discovery Ltd Compostos de mercaptoalquilpeptidila que apresentam um substituinte imdazol e seu uso como inibidores de metaloproteinases de matriz (mmp) e/ou como fator de necrose de tumores (tnf).
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
KR100338861B1 (ko) 1996-01-23 2003-02-20 시오노기세이야쿠가부시키가이샤 술폰화아미노산유도체및이를함유한메탈로프로테이나제저해제
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
ES2169857T3 (es) * 1996-04-04 2002-07-16 Hoffmann La Roche Uso de derivados de tetrahidro-beta-carbolinas como agentes antimetastaticos.
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
PL331369A1 (en) * 1996-07-22 1999-07-05 Monsanto Co Thiosulphonic metaloprotease inhibitors
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
ES2212270T3 (es) * 1997-03-03 2004-07-16 Darwin Discovery Limited Inhibidores selectivos de metaloproteinasas matriciales (mmp) con efectos secundarios reducidos.
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
ES2206903T3 (es) 1997-03-04 2004-05-16 Monsanto Company Compuestos sulfonilicos divalentes de acido aril o heteroaril-hidroxamco.
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
RU2250105C2 (ru) 1997-11-14 2005-04-20 Дж.Д.Сёрл ЛЛС Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
JP2002534410A (ja) * 1998-12-31 2002-10-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド アミドマロンアミド類およびマトリックスメタロプロテイナーゼ阻害剤としてのそれらの用途
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
EP1157021A1 (en) 1999-02-08 2001-11-28 G.D. SEARLE & CO. Sulfamato hydroxamic acid metalloprotease inhibitor
JP2003521476A (ja) * 1999-06-15 2003-07-15 メルク エンド カムパニー インコーポレーテッド チオール誘導体、メタロ−β−ラクタマーゼ阻害剤
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
EP1265865A2 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
NZ520657A (en) * 2000-03-21 2004-11-26 Procter & Gamble Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
CN1418209A (zh) * 2000-03-21 2003-05-14 宝洁公司 含碳环侧链的金属蛋白酶抑制剂
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
YU85403A (sh) 2001-05-11 2006-03-03 Pharmacia Corporation Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
WO2004017996A1 (ja) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. 関節軟骨細胞外マトリクス分解阻害剤
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7570250B2 (en) * 2006-05-04 2009-08-04 Yi-Ming Tseng Control device including a ball that stores data
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU599736B2 (en) * 1986-12-24 1990-07-26 Beecham Group Plc Thiol-carboxylic acid derivatives
DE3889726T2 (de) * 1987-03-17 1994-10-13 Res Corp Technologies Inc Synthetische inhibitoren von säugetier-collagenase.
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
WO1994007481A1 (en) * 1992-10-02 1994-04-14 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents

Also Published As

Publication number Publication date
GR3033103T3 (en) 2000-08-31
CZ134996A3 (en) 1996-10-16
DK0728144T3 (da) 2000-07-03
BR9408025A (pt) 1996-12-17
DE69422726T2 (de) 2000-06-08
EP0728144A1 (en) 1996-08-28
CZ287780B6 (en) 2001-02-14
PT728144E (pt) 2000-07-31
JPH09505041A (ja) 1997-05-20
NO961888D0 (no) 1996-05-09
AU679286B2 (en) 1997-06-26
US5853623A (en) 1998-12-29
NO961888L (no) 1996-05-09
ATE188969T1 (de) 2000-02-15
AU8113394A (en) 1995-05-29
WO1995013289A1 (en) 1995-05-18
ES2143611T3 (es) 2000-05-16
GB9323165D0 (en) 1994-01-05
CN1134705A (zh) 1996-10-30
KR960705843A (ko) 1996-11-08
DE69422726D1 (de) 2000-02-24
FI961976A0 (fi) 1996-05-09
EP0728144B1 (en) 2000-01-19
PL314300A1 (en) 1996-09-02
HU9601244D0 (en) 1996-07-29
HUT73799A (en) 1996-09-30
PL180403B1 (pl) 2001-01-31
HK1015139A1 (en) 1999-10-08
HU217344B1 (hu) 2002-02-28
CA2173470A1 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
FI961976A7 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
FI960803A7 (fi) TNF-alfa-sekreetion inhibiittoreita
FI961819L (fi) Proteiini:farnesyylitransferaasin substituoidut di- ja tripeptidi-inhibiittorit
FI954718A0 (fi) Heterosykliset johdannaiset iskeemian ja vastaavien sairauksien hoitamiseksi
FI935020A7 (fi) Interleukiini-1b-proteaasi ja interleukiini-1b-proteaasin inhibiittoreita
FI943728L (fi) Enkefalinaasin ja ACE:n inhibiittoreina käyttökelpoisia uusia aminoasetyylimerkaptojohdannaisia
FI941766A7 (fi) sPLA2:n 1H-indoli-3-etikkahappohydratsidi-inhibiittoreita
FI925787A7 (fi) Proeteolyyttisten entsyymien sakkariinijohdannaisinhibiittoreita
KR950704251A (ko) 프롤릴 엔도펩티다아제 억제 활성을 갖는 화합물 및 그 약학적 용도(compound with prolyl endopeptdase inhibitor activity and pharmaceutical use thereof)
FI943231A7 (fi) Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnoksia
FI954580L (fi) HIV-proteaasin estäjiä farmaseuttisissa yhdistelmissä käytettäväksi AIDSin hoitoon
NO972477D0 (no) Meso-mono-jod substituerte tetramakrocykliske forbindelser og fremgangsmåter for fremstilling og anvendelse
FI951306A0 (fi) Otsoniystävällinen sterilointiaineseos
FI935172A7 (fi) Katepsiini G:n ja elastaasin inhibiittoreita sidekudoksen rappeutumise n ehkäisemistä varten
FI965204A0 (fi) Bromelaiinin lääkekäyttö
FI895046A7 (fi) 4-amino-3-asyylikinoliinijohdannaiset ja niiden käyttö mahanesteiden e rittymisen estäjinä
UA10998C2 (uk) Спосіб поліфакторhої лікувальhої дії та ковдра для поліфакторhої лікувальhої дії
FI952458A7 (fi) Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-anta gonisteina
ITMI930341A1 (it) Impiego terapeutico del pirrolidon carbossilato di piridossina
FI931701A7 (fi) Rasvan muodostumista ehkäisevän tekijän johdannaiset, niiden valmistus ja käyttö
NO955258D0 (no) Medisinsk anvendelse av enzymer
NO934317D0 (no) Anvendelse av visse metanbisfosfonsyrederivater i brudd-heling
FI962019L (fi) Pyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina